tetano
Editor, Senior Moderator
Microb Pathog
. 2023 Sep 23;106356.
doi: 10.1016/j.micpath.2023.106356. Online ahead of print. Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19
Sushant Sunder[SUP] 1 [/SUP], Kriti Bhandari[SUP] 1 [/SUP], Shruti Sounkaria[SUP] 1 [/SUP], Manjari Vyas[SUP] 1 [/SUP], Bhupendra Pratap Singh[SUP] 2 [/SUP], Prakash Chandra[SUP] 3 [/SUP]
Affiliations
The world has witnessed the cruelty of COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of COVID-19 with other secondary and bacterial co-infections has tremendously contributed to lung infections. An increased probability of having a secondary lung infection was observed among the post-COVID patients. The treatment of antibiotics has ameliorated the mortality rate. However, the stewardship of antibiotic treatment was linked to increased organ failure. Therefore, the paper discusses the interactions between the virus and host through the ACE2 receptors that contribute to COVID-19 development. Furthermore, the paper provides an invaluable compendium history of SARS-CoV-2 genomic composition. It revolves around most classes of antibiotics used to treat COVID-19 disease and post-COVID lung infections with the complete mechanism. This binds with the exertion of the antibiotics for bacterial infection associated with COVID-19 patients and how beneficial and effective responses have been recorded for the treatment. The application of nanotechnology and possible approaches of nanomedicines is also discussed to its potential usage.
Keywords: Antibiotics; COVID-19; Gram-negative bacteria; Nanoparticles; Pathogens.
. 2023 Sep 23;106356.
doi: 10.1016/j.micpath.2023.106356. Online ahead of print. Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19
Sushant Sunder[SUP] 1 [/SUP], Kriti Bhandari[SUP] 1 [/SUP], Shruti Sounkaria[SUP] 1 [/SUP], Manjari Vyas[SUP] 1 [/SUP], Bhupendra Pratap Singh[SUP] 2 [/SUP], Prakash Chandra[SUP] 3 [/SUP]
Affiliations
- PMID: 37743025
- DOI: 10.1016/j.micpath.2023.106356
The world has witnessed the cruelty of COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of COVID-19 with other secondary and bacterial co-infections has tremendously contributed to lung infections. An increased probability of having a secondary lung infection was observed among the post-COVID patients. The treatment of antibiotics has ameliorated the mortality rate. However, the stewardship of antibiotic treatment was linked to increased organ failure. Therefore, the paper discusses the interactions between the virus and host through the ACE2 receptors that contribute to COVID-19 development. Furthermore, the paper provides an invaluable compendium history of SARS-CoV-2 genomic composition. It revolves around most classes of antibiotics used to treat COVID-19 disease and post-COVID lung infections with the complete mechanism. This binds with the exertion of the antibiotics for bacterial infection associated with COVID-19 patients and how beneficial and effective responses have been recorded for the treatment. The application of nanotechnology and possible approaches of nanomedicines is also discussed to its potential usage.
Keywords: Antibiotics; COVID-19; Gram-negative bacteria; Nanoparticles; Pathogens.